ZYUS Life Sciences’ (ZYU) “Buy” Rating Reiterated at Roth Capital
Roth Capital reiterated their buy rating on shares of ZYUS Life Sciences (CVE:ZYU – Free Report) in a report published on Thursday, PriceTargets.com reports. Separately, Stifel Canada reissued a speculative buy rating on shares of ZYUS Life Sciences in a research note on Friday, January 26th. Check Out Our Latest Research Report on ZYUS Life […]
More Stories
Hegseth, Rubio Brief Lawmakers on US Operation in Venezuela
By Joseph Lord and Nathan Worcester WASHINGTON—Secretary of War Pete Hegseth and Secretary of State Marco Rubio on Monday briefed...
Ford Reports Best Annual US Vehicle Sales in 8 Years as Hybrids, Trucks Offset EV Slowdown
By Tom Ozimek Ford Motor Company on Jan. 6 reported its strongest annual U.S. vehicle sales since 2019, buoyed by...
Trucking Insiders Reveal How Licensing System Enabled Illegal Immigrant Drivers
By Jacob Burg When a semi-truck driver made an illegal U-turn on the Florida Turnpike in August 2025, causing the...
Venezuelan Opposition Leader Machado Hails Trump for Capture of Maduro
By Kimberly Hayek Venezuelan opposition leader Maria Corina Machado celebrated President Donald Trump for making the decision to capture Nicolás...
Morgan Stanley Lifts Gold Forecast to $4,800, Citing Fed Cuts and Global Risk
By Tom Ozimek Gold prices are poised to climb to fresh record highs by the end of the year, with...
Key Takeaways From Maduro’s First Court Appearance
By Arjun Singh and Sam Dorman NEW YORK CITY—Deposed Venezuelan leader Nicolás Maduro and his wife, Cilia Flores, made their...